in postmenopausal women with ER-negative breast cancer, although these women did have a reduced O/E. There was no effect at all on premenopausal women.
Risk of malignant brain tumor as a second primary is significantly reduced after treatment of breast cancer
To the Editor:
Treatment of glioblastoma, which represents 60%-75% of primary malignant brain tumors, remains unsatisfactory, and overall mortality is high. Standard treatment includes maximal surgical resection, radiation therapy, and chemotherapy with temozolomide. A recent study showed that the addition of bevacizumab (Avastin) to radiotherapy and temozolomide did not improve survival, but did improve progression-free survival, maintenance of baseline quality of life, and performance status. However, the rate of adverse events was higher with bevacizumab than with placebo. 1 Glioblastoma and breast cancer share pathophysiologic characteristics:
• PTEN, a protein tyrosine phosphatase gene, is mutated in human brain and breast cancer. • An epidermal growth factor receptor-targeted synthetic doublestranded RNA eliminated glioblastoma, breast cancer, and adenocarcinomas in mice. 4 We now report that the risk of malignant brain tumor as a second primary is reduced after treatment of breast cancer. Our finding suggests that aromatase inhibitor therapy for breast cancer might be helpful to patients with glioblastoma, even though results of treatment with the selective estrogen receptor modulator tamoxifen have been disappointing. 5 The study population was assembled using records from the 
